ReviewFrontiers in neurology2022
Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate?
Review in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Review
- Knowledge graph-guided multiple sclerosis identification and therapeutic trend analysis: Real-world evidence from two large healthcare systems.PLOS digital health · 2026Article
- Glatiramer Acetate Therapy Induces DNA Methylation Changes in Immune Cells of Multiple Sclerosis Patients: A Pilot Study.International journal of molecular sciences · 2026Article
- Ganoderma lucidum mediates microglial polarization and ameliorates experimental autoimmune encephalomyelitis by reducing oxidative stress and inhibiting NF-κB/STAT3 pathway.Chinese medicine · 2026Article
- Therapeutic Potential of Plant-based Flavonoids in the Management of Multiple Sclerosis.Current neurovascular research · 2026Article
- Investigation of the effects of alcoholic frankincense extract on oxidative stress and inflammatory parameters in C57BL/6 mice with induced autoimmune encephalomyelitis.Avicenna journal of phytomedicine · 2026Article
- Crocin as a multimodal therapy for multiple sclerosis: Recent breakthroughs in immunomodulation and neuroprotection.Current journal of neurology · 2025Article
- A Review of the Impact of Platform Therapies (DMTs) on Associated Clinical Symptoms of Multiple Sclerosis.Journal of multidisciplinary healthcare · 2025Review
- A narrative review on the safety of glatiramer acetate in multiple sclerosis: focus on Europe.Therapeutic advances in chronic disease · 2025Review
- The Compelling Role of Brain-Derived Neurotrophic Factor Signaling in Multiple Sclerosis: Role of BDNF Activators.CNS neuroscience & therapeutics · 2024Review
- Slow Subcutaneous Release of Glatiramer Acetate or CD40-Targeting Peptide KGYYNeurology international · 2024Article
- Nano-based approaches for the treatment of neuro-immunological disorders: a special emphasis on multiple sclerosis.Discover nano · 2024Review
- BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair.Acta neuropathologica · 2024Article
- Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Earlier diagnosis, access to disease-modifying therapies (DMTs), and improved supportive care have favorably altered the disease course of multiple sclerosis (MS), leading to an improvement in long-term outcomes for people with MS (PwMS). This success has changed the medical characteristics of the population seen in MS clinics. Comorbidities and the accompanying polypharmacy, immune senescence, and the growing number of approved DMTs make selecting the optimal agent for an individual patient more challenging. Glatiramer acetate (GA), a moderately effective DMT, interacts only minimally with comorbidities, other medications, or immune senescence. We describe here several populations in which GA may represent a useful treatment option to overcome challenges due to advanced age or comorbidities (e.g., hepatic or renal disease, cancer). Further, we weigh GA's potential merits in other settings where PwMS and their neurologists must base treatment decisions on factors other than selecting the most effective DMT, e.g., family planning, conception and pregnancy, or the need for vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.